# Gossypol Acetic Acid in Treating Patients With Recurrent, Metastatic, or Primary Adrenocortical Cancer That Cannot Be Removed By Surgery

> **NCT00848016** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 29 (actual)

## Conditions studied

- Recurrent Adrenocortical Carcinoma
- Stage III Adrenocortical Carcinoma
- Stage IV Adrenocortical Carcinoma

## Interventions

- **DRUG:** R-(-)-gossypol acetic acid

## Key facts

- **NCT ID:** NCT00848016
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-02
- **Primary completion:** 2012-03
- **Final completion:** 2012-06
- **Target enrollment:** 29 (ACTUAL)
- **Last updated:** 2014-05-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00848016

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00848016, "Gossypol Acetic Acid in Treating Patients With Recurrent, Metastatic, or Primary Adrenocortical Cancer That Cannot Be Removed By Surgery". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT00848016. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*